Published in Blood on February 17, 2009
Acute lymphoblastic leukaemia. Lancet (2013) 3.44
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Secondary Solid Organ Neoplasm in Patients with Acute Lymphoblastic Leukemia: A Nationwide Population-Based Study in Taiwan. PLoS One (2016) 1.38
Optimizing treatment in paediatric rheumatology--lessons from oncology. Nat Rev Rheumatol (2015) 0.99
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol (2013) 0.96
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol (2014) 0.95
A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia (2014) 0.95
Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol (2014) 0.86
Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment. PLoS One (2014) 0.84
Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics (2011) 0.83
Relative fitness of hematopoietic progenitors influences leukemia progression. Leukemia (2011) 0.83
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol (2014) 0.83
Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics (2014) 0.83
The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia (2009) 0.83
Folate levels modulate oncogene-induced replication stress and tumorigenicity. EMBO Mol Med (2015) 0.82
Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia. Clin Proteomics (2011) 0.82
Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose Optimization. PLoS One (2015) 0.82
Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J (2015) 0.81
Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia. Med Oncol (2013) 0.81
Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries. Mediterr J Hematol Infect Dis (2011) 0.78
Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain. World J Gastroenterol (2013) 0.77
The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair. Mol Cancer Res (2011) 0.76
Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics (2016) 0.75
Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy? Therap Adv Gastroenterol (2016) 0.75
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. Pharmgenomics Pers Med (2017) 0.75
Screening of cytoprotectors against methotrexate-induced cytogenotoxicity from bioactive phytochemicals. PeerJ (2016) 0.75
On the malignant potential of thiopurine therapy. Blood (2009) 0.75
Maintenance loses its innocence. Blood (2009) 0.75
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol (1992) 2.53
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer (2008) 2.24
Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science (1996) 2.05
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1978) 1.81
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene (2006) 1.62
Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood (2002) 1.54
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood (2003) 1.51
Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst (2007) 1.34
Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia (2008) 1.33
Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res (1995) 1.29
Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry (1997) 1.26
Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol (2006) 1.15
Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia (1998) 1.14
Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer (1999) 1.13
The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev (1985) 1.12
Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr (1998) 1.12
Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia (2000) 1.08
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood (1990) 1.08
Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia (2007) 1.04
High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2007) 1.04
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics (2002) 1.03
High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia (2006) 1.02
Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.01
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia (1995) 1.00
Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (NOPHO). Acta Paediatr Scand (1991) 0.98
Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia (2000) 0.98
Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol (2008) 0.95
Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol (2001) 0.94
Susceptibility to chromosome malsegregation in lymphocytes of women who had a Down syndrome child in young age. Neurobiol Aging (2005) 0.92
Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol (1998) 0.92
Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2001) 0.91
Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol (1996) 0.90
Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia (2002) 0.86
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. Haematologica (2007) 0.86
High-resolution comparative genomic hybridisation yields a high detection rate of chromosomal aberrations in childhood acute lymphoblastic leukaemia. Eur J Haematol (2003) 0.86
GST polymorphisms and occurrence of second neoplasms after treatment of childhood leukemia. Leukemia (2003) 0.85
6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia (2001) 0.85
Treatment-related leukaemia--a clinical and scientific challenge. Cancer Treat Rev (2000) 0.83
Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia. Leukemia (2003) 0.83
Secondary brain tumours in children with ALL. Lancet (1999) 0.81
Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol (2000) 0.80
Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Am J Hematol (2008) 0.79
Increased availability of phosphoribosyl pyrophosphate as the basis for enhanced 6-mercaptopurine incorporation by methotrexate, in cultured human lymphoblasts. Adv Exp Med Biol (1986) 0.79
Determination of leukocyte DNA 6-thioguanine nucleotide levels by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.78
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ (2009) 3.44
Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates. Blood (2010) 2.98
Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial. Ann Intern Med (2011) 2.90
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood (2004) 2.62
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood (2012) 2.39
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A (2006) 2.08
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol (2013) 1.97
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res (2007) 1.85
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood (2005) 1.80
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood (2011) 1.74
CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol (2006) 1.66
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Ovarian granulosa cell tumors in childhood. Pediatr Hematol Oncol (2002) 1.59
Nighttime exposure to electromagnetic fields and childhood leukemia: an extended pooled analysis. Am J Epidemiol (2007) 1.58
Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol (2013) 1.57
Induced abortions in Danish cancer survivors: a population-based cohort study. J Natl Cancer Inst (2009) 1.56
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 1.56
Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis (2008) 1.55
The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. Hum Mutat (2015) 1.46
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol (2009) 1.44
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood (2009) 1.42
A high circulating copy number of HHV-6 due to chromosomal integration in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.41
[23 physicians comments on circumcision of small boys: The Swedish Medical Association should take a more humble approach]. Lakartidningen (2014) 1.40
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2008) 1.39
Blood clot obstruction of the jejunojejunostomy after laparoscopic gastric bypass. Surg Obes Relat Dis (2012) 1.38
Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2010) 1.37
Spontaneous abortion in a Danish population-based cohort of childhood cancer survivors. J Clin Oncol (2008) 1.37
Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet (2011) 1.36
Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci U S A (2005) 1.36
WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol (2004) 1.36
Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol (2003) 1.36
Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica (2008) 1.32
Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics (2013) 1.30
Birth weight and risk for childhood leukemia in Denmark, Sweden, Norway, and Iceland. J Natl Cancer Inst (2004) 1.29
Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell (2005) 1.29
Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood (2010) 1.28
Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood (2002) 1.27
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood (2011) 1.25
Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol (2010) 1.25
The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet (2009) 1.23
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood (2007) 1.23
Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol (2003) 1.22
Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol (2005) 1.22
Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol (2010) 1.21
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood (2011) 1.17
Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis (2012) 1.17
Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer (2010) 1.16
Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol (2006) 1.15
Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril (2010) 1.15
Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp Cell Res (2007) 1.14
Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood (2011) 1.12
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics (2003) 1.12
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood (2011) 1.11
Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet (2003) 1.10
Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med (2010) 1.09
Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood (2008) 1.07
Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2005) 1.06
Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol (2003) 1.05
Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood (2010) 1.05
Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood (2012) 1.04
Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood (2009) 1.03
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer (2007) 1.03
Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5'-flanking region single nucleotide polymorphism (SNP). Biochem Pharmacol (2002) 1.03
Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res (2008) 1.02
Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.01
Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer (2010) 1.01
Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol (2007) 1.01
MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors. Blood (2011) 0.99
CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res (2008) 0.99
Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. Hum Mutat (2010) 0.99
A novel missense mutation (G43S) in the switch I region of Rab27A causing Griscelli syndrome. Mol Genet Metab (2008) 0.99
Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol (2008) 0.99